Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Q2 2021 Earnings Presentation
16 slides from Orasure Technologies's earnings presentation, Aug 3, 2021
Slide 1: OraSure 2Q21 Earnings
OraSure 2Q21 Earnings August 3, 2021 EXHIBIT 99.3
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause act
Slide 3: 2Q21 Financial Results
2Q21 Financial Results FINANCIAL METRIC 2Q21 RESULTS 2Q20 RESULTS GROWTH RATE 2Q21 Total Revenue $57.6 million $29.3 million 97% 2Q21 Total Revenue Excluding COVID-19 Product Revenue $46.0 million $20.8 million 122% 2Q21 COVID-19 Product Revenue $11.6 million $8.5 million 36%
Slide 4: Key Focus Areas to Drive Shareholder Value
Key Focus Areas to Drive Shareholder Value Expand Global Commercial Capabilities and Reach Drive Higher Growth Through Expanded R&D and M&A Expand Into New Sample Types and New Testing Modalities in Molecular Solutions Capitalize on COVID-19 Testing Opportunity To Fund Future Growth
Slide 5: InteliSwab: Designed to be the Simplest COVID-19 Test on the Market
InteliSwab™: Designed to be the Simplest COVID-19 Test on the Market Authorized by FDA for OTC, Prescription Home Use and Professional Point-of-Care CLIA-Waived use Accuracy comparable to other point-of-care offerings (84% sensitivity / 98% specificity) Convenient sample collection with <1 min. of h
Slide 6: Colli-Pee, New Innovation in Sample Collection; Addressing Global HPV Screening Market
Colli-Pee®, New Innovation in Sample Collection; Addressing Global HPV Screening Market 95%, 95% CI (0.88-1.01) 97%, 95% CI (0.89-1.05) Relative Sensitivity Statistically Equivalent *Van Keer et al., https://doi.org/10.1016/j.ygyno.2021.06.010
Slide 7: Microbiome Becoming an Increasingly Important Growth Driver
Microbiome Becoming an Increasingly Important Growth Driver Upcoming Catalysts: Maturity of clinical trials in progress Meta-transcriptome launch New gut collection kit >50 Commercial Customers >30 Bio-Pharma Customers >20 Clinical Studies Partnered with top-5 companies in microbiome space Working w
Slide 8: Expanding Molecular Collection Device Competitiveness Through Multiple Strategies
Expanding Molecular Collection Device Competitiveness Through Multiple Strategies Expanding intellectual property portfolio through filed patents and technology acquisitions (38 patents filed to date on collection devices) Long-term contracts with major customers providing forward visibility Increas
Slide 9: Expanding Global Reach To Broaden Market Access
Expanding Global Reach To Broaden Market Access We now have over 400 product registrations in 95 countries globally
Slide 10: Actively Evaluating Strategically Sound M&A Opportunities
Actively Evaluating Strategically Sound M&A Opportunities DIAGNOSTICS MOLECULAR SOLUTIONS Leverage existing end-to-end infrastructure from research to commercialization Support effortless testing in the POC and self-test settings New technology platforms enable menu expansion Support higher growth r
Slide 11: Revenue in Key Diagnostic Testing Categories
Revenue in Key Diagnostic Testing Categories Test Revenue (in mil.) Diagnostic business recovering from COVID-19 pandemic. COVID-19 testing revenue expected to begin to increase in Q321 Recovering From Pandemic & Launching COVID-19 Antigen Test
Slide 12: Strong Core Growth in Molecular Solutions
Strong Core Growth in Molecular Solutions Test Revenue (in mil.) Overall Revenue + 103% Non-COVID Revenue +158% One of Strongest Quarters Ever from Genomics & Microbiome Services Core revenue up 45% from pre-pandemic levels
Slide 13: Financial Results
Financial Results ne 30 or 708 Rests of Operations Netevanes 3 os § B20 Cosofyoduats muiservees sold 25934 n1g9s os profit 25 T7358 Operaingespanses: Rereuchand devebpaat ami ae Subs ed makeing msn pri Conera and aduanettae 10993 wz0 Change nfarvale of cqustonselted contngmt consideration feet (0, T
Slide 14: 3Q21 Financial Guidance & FY21 InteliSwab Guidance
3Q21 Financial Guidance & FY21 InteliSwab™ Guidance GUIDANCE METRIC FINANCIAL GUIDANCE 3Q21 Total Revenue $45 - $50 million FY21 InteliSwab™ Revenue ≈$30 million FY21 Total Revenue ≈$230 million
Slide 15: Summary
Summary Commercially tied to high growth areas of healthcare such as consumer/clinical genomics and shift to direct-to-patient/near patient testing Increased investment in internal R&D pipeline and reinvigorating innovation Significant opportunity with COVID-19 testing solutions to drive growth and
Slide 16: Q&A
Q&A OraSure Technologies oNAgenoTeK” Diversigen’ Wnovosanis